By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.
Oncotarget
; 6(4): 2315-30, 2015 Feb 10.
Article
em En
| MEDLINE
| ID: mdl-25537513
ABSTRACT
Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer through Polo-like kinase1 (Plk1) down-regulation. Moreover, miR-100 favors BrCSC differentiation, converting a basal like phenotype into luminal. It induces the expression of a functional estrogen receptor (ER) and renders basal-like BrCSCs responsive to hormonal therapy. The key role played by miR-100 in breast cancer free-survival is confirmed by the analysis of a cohort of patients' tumors, which shows that low expression of miR-100 is a negative prognostic factor and is associated with gene signatures of high grade undifferentiated tumors. Our findings indicate a new possible therapeutic strategy, which could make aggressive breast cancers responsive to standard treatments.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Células-Tronco Neoplásicas
/
Neoplasias da Mama
/
Diferenciação Celular
/
MicroRNAs
Tipo de estudo:
Prognostic_studies
Limite:
Aged80
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article